Please login to the form below

Not currently logged in
Email:
Password:

pegpleranib

This page shows the latest pegpleranib news and features for those working in and with pharma, biotech and healthcare.

Novartis buys two firms in pre-Christmas shopping spree

Novartis buys two firms in pre-Christmas shopping spree

Those only gathered pace after a late-stage setback for age-related macular degeneration (AMD) therapy Fovista (pegpleranib), which was licensed by the company in 2014 in a deal valued at

Latest news

  • Novartis' AMD drug pegpleranib fails phase III programme Novartis' AMD drug pegpleranib fails phase III programme

    Novartis' hopes of positioning pegpleranib as a duo alongside its big-selling age-related macular degeneration (AMD) drug Lucentis have been dashed. ... The key message from the data is that the proven efficacy of Lucentis monotherapy was not improved by

  • Novartis says Cosentyx is 'outpacing competitors' Novartis says Cosentyx is 'outpacing competitors'

    These include RLX030 (serelaxin) for acute heart failure, Fovista (pegpleranib) and RTH258 (brolucizumab) for neovascular age-related macular degeneration (AMD), and novel migraine prevention drug AMG334.

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...